What do nicotine pouches do to heart rate and blood pressure?

Why can nicotine change cardiovascular measurements?

Nicotine stimulates autonomic pathways and catecholamine release. That can increase heart rate, constrict some blood vessels and raise blood pressure and myocardial workload. The response depends on how quickly nicotine reaches circulation, the amount delivered and a person’s tolerance and underlying health.

Pouches avoid carbon monoxide and many toxic products created by cigarette combustion, so their cardiovascular exposure profile is not the same as smoking. Removing smoke does not remove nicotine’s acute pharmacological effects, and lower comparative exposure is not the same claim as no cardiovascular effect.

What have direct pouch studies measured?

A 2024 crossover study gave 15 regular cigarette smokers nicotine-free, 6 mg, 20 mg and 30 mg pouches, plus a cigarette, in separate sessions. During use, heart rate increased by about 12 bpm with the 20 mg pouch and 25 bpm with the 30 mg pouch, compared with about 27 bpm for the cigarette. The 30 mg pouch produced higher peak and total nicotine exposure than the cigarette in that experiment.

Other small crossover work has found transient changes in pulse and blood pressure across pouches, snus and nicotine gum. These studies are useful for time-course and dose signals, but they involve selected nicotine-experienced adults under controlled, single-use conditions. They do not represent chronic use or people with cardiovascular disease.

What does an acute cardiovascular response mean?

An acute response is a change occurring during or shortly after exposure. Researchers measure pulse, systolic and diastolic blood pressure, arterial stiffness and sometimes electrocardiographic variables at repeated time points. Those measurements show pharmacological activity and help identify dose-related effects.

They do not by themselves show clinical injury. A temporary rise in pulse is not a heart attack, and a single-session blood-pressure change is not a diagnosis of hypertension. At the same time, a reproducible change is not meaningless: it increases cardiac workload and may matter more for people with underlying disease or unusually high exposure.

Interpretation therefore needs two layers. The direct evidence can establish that a product changes a measurement under specified conditions. A claim about chronic disease requires longer follow-up, appropriate comparison groups and enough participants to observe uncommon outcomes.

What did the high-dose crossover study show?

The 2024 study enrolled 15 regular cigarette smokers and tested five separate conditions: nicotine-free pouches, pouches containing 6 mg, 20 mg or 30 mg nicotine, and a cigarette. Each participant served as their own comparator. Researchers measured plasma nicotine, craving, side effects and cardiovascular parameters over four hours.

The 30 mg pouch produced a peak plasma nicotine concentration of 29.4 ng/mL compared with 15.2 ng/mL for the cigarette, and its total exposure measure was also higher. Heart rate increased by about 25 bpm during the 30 mg condition, close to the roughly 27 bpm cigarette response; the 20 mg pouch produced an increase of about 12 bpm. Arterial-stiffness parameters also rose.

The experiment demonstrates that a high-content pouch can deliver substantial nicotine and produce an acute cardiovascular response. It does not show that all 30 mg products behave identically, because extraction differed across brands, or that a single session predicts long-term events. Its tiny, nicotine-tolerant sample is a major limit on generalization.

What do lower-dose and comparative studies add?

The German BfR assessment summarized a study of 3 mg and 6 mg pouches in experienced users. Median maximum heart-rate change was 8.5 bpm for 3 mg and 10.5 bpm for 6 mg, with the higher-dose response statistically greater. Individual ranges were wide, illustrating that the printed content does not fully predict response.

A separate randomized crossover study compared Nordic Spirit pouches at several strengths with snus and nicotine gum. During the 30-minute use period, mean vital signs rose modestly across products; changes one hour after the start were generally closer to baseline. The authors characterized them as transient. The study was product-specific and involved nicotine users, so it cannot define a universal pouch response.

Together, the studies support a graded but noisy picture: nicotine delivery can raise heart rate and blood pressure, higher or faster exposure can produce larger effects, and some changes recede after use. They do not supply a single conversion from milligrams on the label to beats per minute or blood-pressure change.

Why do content, release and tolerance matter?

Nominal nicotine content is the amount in the unused pouch. The portion released during use and absorbed systemically depends on moisture, pH, formulation and contact time. In the high-dose study, extraction rates differed between products, which helps explain why equal-looking numbers need not produce equal blood concentrations.

Regular nicotine users can develop tolerance to some subjective and hemodynamic effects. A study in smokers or snus users may therefore underestimate the response of a nicotine-naive person. Conversely, comparing habitual users with non-users can be confounded by baseline health, prior smoking and the timing of the last dose.

Frequency matters as well. A transient effect after one pouch may recur repeatedly when pouches are used throughout the day. Single-dose experiments identify peaks but do not measure the cumulative pattern created by overlapping use, sleep disruption, caffeine, stress or other exposures.

What did the cessation cohort establish?

A Swedish cohort followed daily users of tobacco snus or nicotine pouches after abrupt cessation. Among those included in the analysis, heart rate fell by an average of 5.7 bpm during the first week, while systolic home blood pressure increased by 3.7 mmHg by week 12. Body weight also increased. These directions show why long-term physiology cannot be inferred from the acute response alone.

The study combined tobacco-containing and tobacco-free pouch users, was not randomized and included only dozens of participants. Changes after cessation can reflect withdrawal, weight change, diet, stress and regression toward baseline as well as removal of nicotine. It cannot isolate the chronic effect of modern nicotine pouches.

Its value is to challenge simplistic expectations. Stopping a stimulant can lower pulse quickly while other metabolic or behavioural changes move blood pressure in another direction. Long-term health assessment needs multiple measurements and an appropriate control group, not one before-and-after number.

Can current evidence quantify heart-attack or stroke risk?

No pouch-specific study currently provides a reliable long-term estimate for myocardial infarction, stroke, arrhythmia or cardiovascular mortality. Such outcomes require large cohorts, careful adjustment for previous smoking and other risk factors, exact product histories and years of follow-up.

Evidence from nicotine pharmacology and other products makes cardiovascular concern biologically plausible, but transporting a risk estimate from cigarettes, snus or nicotine-replacement therapy would be misleading. Cigarettes add combustion exposures; medicinal nicotine uses different formulations and populations; snus contains tobacco and has a longer epidemiological history.

The correct conclusion is therefore neither “no evidence of harm” nor “equivalent to smoking.” Pouches can acutely affect cardiovascular function, while the magnitude of chronic pouch-specific disease risk remains unknown.

What evidence would make the long-term answer stronger?

Prospective cohorts should enroll users before disease develops and repeatedly record exact brand, strength, frequency, duration, concurrent nicotine use and smoking history. Ambulatory blood pressure and validated cardiovascular outcomes would be stronger than one clinic measurement or self-reported diagnosis.

Randomized short-term studies can improve dose and formulation comparisons by including placebo pouches, blinded conditions and participants with different tolerance. They should report individual responses and adverse events, not only group averages. Studies in people with established cardiovascular disease require particular safeguards and clinical oversight.

Independent replication and transparent funding are essential. Product manufacturers can supply formulation data and standardized products, but protocols, analysis plans and unfavourable results should be public. Regulators and clinicians need evidence that distinguishes acute pharmacology, sustained risk-factor change and actual clinical events.